HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
To compare the antitumor efficacy and toxicity of Idarubicin and cytarabine in combination
with or not with infusions of granulocyte colony-stimulating factor-mobilized HLA-mismatched
donor peripheral blood stem cells in patients with newly diagnosed high-risk acute myeloid
leukemia (AML).
Phase:
Phase 3
Details
Lead Sponsor:
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences